Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice

[1]  James X. Sun,et al.  Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis , 2019, Annals of Surgical Oncology.

[2]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[3]  R. Emerson,et al.  Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade , 2018, Cancer Immunology Research.

[4]  R. Gonzalez,et al.  Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions , 2017, Annals of Surgical Oncology.

[5]  A. Hauschild,et al.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[7]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[8]  B. Coventry,et al.  Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study , 2017, Annals of Surgical Oncology.

[9]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[10]  I. Puzanov,et al.  Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Coventry,et al.  Australian Multicenter Study of Isolated Limb Infusion for Melanoma , 2016, Annals of surgical oncology.

[12]  Lesly A. Dossett,et al.  Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma , 2016, Annals of Surgical Oncology.

[13]  J. Thomas,et al.  Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma , 2015, Annals of surgical oncology.

[14]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[15]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Shannon,et al.  In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy , 2015, Annals of Surgical Oncology.

[17]  M. Ross,et al.  Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma , 2014, Annals of Surgical Oncology.

[18]  José H. Fregnani,et al.  Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity , 2014, ANZ journal of surgery.

[19]  B. Coventry,et al.  Australian multi‐center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma , 2014, Journal of surgical oncology.

[20]  C. Ariyan,et al.  Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion , 2014, Journal of surgical oncology.

[21]  H. Hoekstra,et al.  Isolated limb perfusion for in‐transit melanoma metastases: Melphalan or TNF‐melphalan perfusion? , 2014, Journal of surgical oncology.

[22]  P. Kam,et al.  Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review , 2014, Journal of surgical oncology.

[23]  D. Tyler,et al.  Resection of Residual Disease after Isolated Limb Infusion (ILI) Is Equivalent to a Complete Response after ILI-Alone in Advanced Extremity Melanoma , 2014, Annals of Surgical Oncology.

[24]  J. Wong,et al.  Isolated Limb Infusion in a Series of Over 100 Infusions: A Single-Center Experience , 2013, Annals of Surgical Oncology.

[25]  M. Dewhirst,et al.  A multi‐institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan‐based isolated limb infusion , 2012, Cancer.

[26]  C. Augustine,et al.  A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity , 2012, Annals of Surgical Oncology.

[27]  D. Tyler,et al.  A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities , 2012, Annals of Surgical Oncology.

[28]  D. Tyler,et al.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion , 2011, Expert opinion on drug metabolism & toxicology.

[29]  A. Testori,et al.  Local and intralesional therapy of in‐transit melanoma metastases , 2011, Journal of surgical oncology.

[30]  J. Gershenwald,et al.  Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate , 2011, Journal of surgical oncology.

[31]  A. Testori,et al.  Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion , 2011, Journal of surgical oncology.

[32]  A. Eggermont,et al.  20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters , 2011, Annals of Surgical Oncology.

[33]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[34]  P. Kam,et al.  Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution , 2011, Annals of Surgical Oncology.

[35]  Merrick I Ross,et al.  Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[37]  S. Mocellin,et al.  Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases , 2010, Annals of Surgical Oncology.

[38]  L. de la Cruz-Merino,et al.  Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. , 2010, The oncologist.

[39]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  K. Harrington,et al.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Beller,et al.  Isolated Limb Infusion for Malignant Melanoma: Predictors of Response and Outcome , 2009, Annals of Surgical Oncology.

[42]  H. Kroon,et al.  Isolated limb infusion: A review , 2009, Journal of surgical oncology.

[43]  M. Ross,et al.  Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis , 2009, Annals of Surgical Oncology.

[44]  M. Ross,et al.  A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. , 2009, Journal of the American College of Surgeons.

[45]  P. Kam,et al.  Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma , 2009, Cancer.

[46]  I. Sperduti,et al.  Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. , 2009, In vivo.

[47]  P. Kam,et al.  Isolated Limb Infusion as Palliative Treatment for Advanced Limb Disease in Patients with AJCC Stage IV Melanoma , 2009, Annals of Surgical Oncology.

[48]  P. Kam,et al.  Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients , 2009, Annals of Surgical Oncology.

[49]  P. Hersey,et al.  Chemoablation of metastatic melanoma using intralesional Rose Bengal , 2008, Melanoma research.

[50]  R. Petersen,et al.  Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion , 2008, Annals of Surgical Oncology.

[51]  P. Kam,et al.  Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience , 2008, Annals of Surgical Oncology.

[52]  S. Soong,et al.  Prognosis and Determinants of Outcome Following Locoregional or Distant Recurrence in Patients with Cutaneous Melanoma , 2008, Annals of Surgical Oncology.

[53]  P. Kam,et al.  Long-term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma: A Reflection of Tumor Biology , 2007, Annals of surgery.

[54]  Jeffrey E. Lee,et al.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  K. Brown,et al.  A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity , 2006, Annals of Surgical Oncology.

[56]  A. Eggermont,et al.  Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[57]  W. Hohenberger,et al.  Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[58]  D. Tyler,et al.  Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. , 2005, Archives of surgery.

[59]  A. Eggermont,et al.  TNF dose reduction in isolated limb perfusion. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[60]  A. Eggermont,et al.  Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure , 2005, Annals of Surgical Oncology.

[61]  A. Eggermont,et al.  Isolated Limb Perfusion Prolongs the Limb Recurrence-Free Interval After Several Episodes of Excisional Surgery for Locoregional Recurrent Melanoma , 2004, Annals of Surgical Oncology.

[62]  P. Kam,et al.  Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[63]  A. Eggermont,et al.  One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases , 2004, Annals of surgery.

[64]  A. Eggermont,et al.  Isolated limb perfusion for unresectable melanoma of the extremities. , 2004, Archives of surgery.

[65]  Jeffrey E. Lee,et al.  Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy , 2004, Annals of Surgical Oncology.

[66]  A. Eggermont,et al.  Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.

[67]  A. Eggermont,et al.  Safety and efficacy of isolated limb perfusion in elderly melanoma patients , 2002, Annals of Surgical Oncology.

[68]  K. McMasters.  Isolated limb perfusion in elderly melanoma patients , 2002, Annals of surgical oncology.

[69]  J. Wilt,et al.  Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role , 2001, Annals of Surgical Oncology.

[70]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[71]  A. Eggermont,et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  P. Kam,et al.  Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. , 1998, Seminars in surgical oncology.

[73]  B. Vrouenraets,et al.  Toxicity and morbidity of isolated limb perfusion. , 1998, Seminars in surgical oncology.

[74]  P. Kam,et al.  Frequency and duration of remission after isolated limb perfusion for melanoma. , 1997, Archives of surgery.

[75]  H. Polk,et al.  Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma , 1997, Annals of Surgical Oncology.

[76]  R. C. Johnson,et al.  A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[77]  B. Vrouenraets,et al.  Thirty‐five years of isolated limb perfusion for melanoma: Indications and results , 1996, The British journal of surgery.

[78]  R. MacKie,et al.  A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. , 1996, European journal of cancer.

[79]  D. Fraker,et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  H. Pichlmaier,et al.  Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. , 1995, American journal of surgery.

[81]  G. Ghanem,et al.  Modulation by cAMP of adhesion molecules expression in HUVEC and human melanoma cells , 1994 .

[82]  A. Eggermont,et al.  Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. , 1994, Melanoma research.

[83]  J. Thompson,et al.  Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs , 1992, World journal of surgery.

[84]  C. Ingvar,et al.  Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  M. Chapman,et al.  Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. , 1991, International journal of radiation oncology, biology, physics.

[86]  D. Coit,et al.  Major amputation for advanced malignant melanoma. , 1989, Surgery, gynecology & obstetrics.

[87]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.

[88]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[89]  C. Verhoef,et al.  Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[90]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[91]  D. Tyler,et al.  Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma , 2014, Annals of Surgical Oncology.

[92]  M. Ross,et al.  A Multicenter Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-arterial Temozolomide for Patients with Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion , 2014, Annals of Surgical Oncology.

[93]  S. Steinberg,et al.  Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[95]  B. S. B. John F. Thompson M.B.,et al.  Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs , 2005, World Journal of Surgery.

[96]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  H. Ed,et al.  Biologic behavior and treatment of intransit metastasis of melanoma. , 1980 .